Presented by: Paul Laikind, Ph.D., President & CEO
ViaCyte, a private company in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company’s lead product candidate, VC-01, is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device called the Encaptra® drug delivery system. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and the Juvenile Diabetes Research Foundation (JDRF).

For more information on the 2014 Stem Cell Meeting on the Mesa visit www.stemcellmeetingonthemesa.com

свернуть